Name: Juvmo (tavapadon) in Parkinson's disease: Pharmacokinetics
Published: 2026-09-27T21:44:59-04:00

Absorption and dose proportionality

“Following oral administration of JUVMO, tavapadon is absorbed with peak plasma concentrations (Cmax) at approximately 2 to 4 hours.” (opens the prescribing information at this quote)
“Tavapadon displays dose-proportional pharmacokinetics within the maintenance dose range of 5 mg to 15 mg.” (opens the prescribing information at this quote)

Effect of food

“When JUVMO was administered with a high-fat/high-calorie meal, the food effect was not significant (AUCτ and Cmax were increased by approximately 10% and 12%, respectively, with no effect on median time to Cmax).” (opens the prescribing information at this quote)
“JUVMO was administered without regard to food in clinical efficacy studies.” (opens the prescribing information at this quote)

Distribution

“Tavapadon plasma protein binding is 93% (primarily albumin).” (opens the prescribing information at this quote)
“The apparent volume of distribution of tavapadon is 63.5 L.” (opens the prescribing information at this quote)

Metabolism, excretion, and half-life

“Tavapadon and its major inactive metabolite M4 are primarily metabolized by CYP3A.” (opens the prescribing information at this quote)
“The AUC ratio of M4 to tavapadon is approximately 1.4.” (opens the prescribing information at this quote)
“Unchanged tavapadon was a minor component in both urine and feces (less than 1%). Metabolite M4 accounted for less than 5% of the administered dose in both urine and feces.” (opens the prescribing information at this quote)
“The mean elimination half-life of tavapadon is approximately 25.5 hours.” (opens the prescribing information at this quote)

Phase 1 pharmacokinetics in Parkinson's disease: single and multiple doses

“Following administration of single oral doses of PF-06649751 from 0.75 mg to 9 mg under fasted conditions, PF-06649751 Cmax occurred at approximately 3.0–4.0 h post dose (Supplementary Fig. 1 top panel and Supplementary Table 3).” (opens the source at this quote in a new tab)
“On day 22 (steady-state), following administration of multiple oral doses of PF-06649751 from 5 mg to 25 mg, mean Cmax for PF-06649751 occurred at approximately 2.0–4.0 h post dose.” (opens the source at this quote in a new tab)
“On the basis of average values in Parkinson’s disease subjects with motor fluctuations (cohort 4 vs cohort 6), the increase in AUCtau was less than dose proportional between 15 mg and 25 mg.” (opens the source at this quote in a new tab)
“The mean apparent clearance values ranged from 2.4 L/h to 3.5 L/h.” (opens the source at this quote in a new tab)

Half-life relative to levodopa and other dopamine agonists

“The half-life of tavapadon is approximately 24 hours” (opens the source at this quote in a new tab)
“which is substantially longer than that of levodopa or standard formulations of many D2/D3-selective DAs” (opens the source at this quote in a new tab)

Mass balance study

“An Open-label Trial to Evaluate the Absorption, Metabolism, and Excretion of a Single Dose of [14C]-Tavapadon in Healthy Adult Male Subjects at Steady State” (opens the source at this quote in a new tab)